Metforminhydrochlorid Al

Metformin Hydrochloride, the active ingredient in Metforminhydrochlorid Al, is a biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults and is commonly prescribed as part of a comprehensive glucose‑lowering regimen.

GNH USA supplies Metforminhydrochlorid Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Metformin Hydrochloride is a biguanide that lowers blood glucose by targeting hepatic glucose production and insulin sensitivity.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes when used with lifestyle measures. - Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity.

Metformin Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: often mild to moderate and transient. - Metallic taste: a transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: may develop with long‑term use. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycemia: typically when combined with other glucose‑lowering agents. - Hepatic failure: rare cases of liver injury. - Allergic skin reactions: rash, pruritus, or urticaria. - Neutropenia: reduced white blood cell count. - Pancreatitis: inflammation of the pancreas.

When prescribing Metformin, clinicians should consider several precautionary measures to minimize risk.

- Renal function: assess eGFR before initiation and periodically thereafter. - Hepatic function: evaluate liver disease prior to use. - Age: start at lower dose in elderly patients. - Alcohol consumption: advise patients to limit intake. - Concomitant medications: review for drugs that may increase risk of lactic acidosis. - Store at room temperature: keep in original container, protect from moisture.

Metformin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: risk of acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis. - Beta‑blockers: can mask hypoglycemia symptoms. - Diuretics (loop, thiazide): may impair renal clearance.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increased risk of hypoglycemia. - DPP‑4 inhibitors: additive glucose‑lowering effect. - ACE inhibitors/ARBs: monitor renal function. - Thyroid hormones: may affect glycemic control. - Antibiotics (e.g., fluoroquinolones): watch for renal function changes.